<DOC>
	<DOCNO>NCT02160756</DOCNO>
	<brief_summary>The purpose study evaluate pharmacokinetics ( PK - study way drug enters leave blood tissue time ) relative bioavailability ( extent drug substance become available body ) JNJ-56021927 , administer 3 tablet formulation ( test ) compare JNJ-54781532 softgel capsule formulation ( reference ) healthy male participant fast condition single dose 240 milligram ( mg ) .</brief_summary>
	<brief_title>Bioavailability Study 3 Tablet Formulations v . Capsule Formulation JNJ-56021927 Fasting Healthy Male Participants</brief_title>
	<detailed_description>This randomize ( study medication assign participant chance ) , open-label ( people know identity intervention ) , single-center , 4-treatment , parallel design ( medical research study compare response two group participant receive different intervention ) study single dose 240 mg JNJ-56021927 . The duration study approximately 78 day per participant . The study consist 3 part : Screening phase ( , 21 day study commences Day 1 ) ; Open-label Treatment phase ( consist 4 parallel single-dose treatment ) ; End-of-Study ( completion Hour 1344 PK sample Day 57 , upon early withdrawal ) . All eligible participant randomly assign 1 4 possible treatment : Treatment A ( 240 mg dose softgel capsule ) ; Treatment B ( 240 mg dose Tablet Formulation 1 ) ; Treatment C ( 240 mg dose Tablet Formulation 2 ) ; Treatment D ( 240 mg dose Tablet Formulation 3 ) . Participants fast overnight food fluid ( exclude non-carbonated water ) least 10 hour study drug administration Day 1 . Blood sample collect pre-dose 1,344 hour ( Day 57 ) dose determination JNJ-56021927 concentration active metabolite . Relative bioavailability 3 tablet formulation compare softgel capsule formulation JNJ-56021927 evaluate primarily . Participants ' safety monitor throughout study .</detailed_description>
	<criteria>Must agree use adequate contraception method deem appropriate investigator , always use condom sexual intercourse , donate sperm study 3 month receive study drug Body mass index 18 30 kilogram ( kg ) per square meter , body weight less 50 kg Blood pressure ( supine 5 minute ) 90 140 millimeter mercury ( mm Hg ) systolic , high 90 mm Hg diastolic A 12lead electrocardiogram ( ECG ) consistent normal cardiac conduction function , include pulse rate 45 99 beat per minute ( bpm ) , QT correct Fridericia ( QTcF ) interval less equal 450 millisecond ( msec ) , QRS interval le 120 msec , PR interval le 220 msec , morphology consistent healthy cardiac conduction function Nonsmoker within previous 2 month History current clinically significant medical illness include ( limited ) cardiac arrhythmia cardiac disease , hematologic disease , coagulation disorder ( include abnormal bleeding blood dyscrasia ) , lipid abnormality , significant pulmonary disease , include bronchospastic respiratory disease , diabetes mellitus , hepatic renal insufficiency , thyroid disease , neurologic psychiatric disease , infection Known hypersensitivity Vitamin E History stomach intestinal surgery resection would potentially alter absorption excretion orally administer drug Known allergy study drug excipients formulation Unable swallow solid , oral dosage form whole aid water</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Healthy</keyword>
	<keyword>JNJ-56021927</keyword>
	<keyword>JNJ-56142060</keyword>
	<keyword>ARN-509</keyword>
</DOC>